Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus

Gynecologic Oncology

Volumn 73, Issue 1, 1999, Pages 27-34

  Wolf, Judith K ^a   Kim, Tae Eung ^a   Fightmaster, Diane ^a   Bodurka, Diane ^a   Gershenson, David M ^a   Mills, Gordon ^a   Wharton, J Taylor ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P16; VIRUS VECTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL COUNT; CELL CYCLE G1 PHASE; CELL SELECTION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032894167     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5259     Document Type: Article

References (31)

1. Serrano M, Hannon G, Beach DA: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
2. Serrano M, Lee HW, Chin L, Cordon-Cando C, Beach D, DiPinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 86:27-37, 1996
3. Kamb A, Gruis NA, Weaver-Feldhaus J, Lui Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 265:436-440, 1994
4. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 238:753-756, 1994
5. Moulton T, Samara G, Chung WY, Yuan C, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146:613-619, 1995
6. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994
7. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomore DA, Nobori T, Olopade OI, Bucker AJ, Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551, 1994
8. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994
9. Jen J, Harper JW, Bigner DD, Papadapoulos N, Markowitz S, Wilson JKV, Kinzler KW, Vogerstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353-6358, 1994
10. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4042, 1994
11. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemias. Blood 85:2699-2704, 1994
12. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1453, 1995
13. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancer. Cancer Res 55:4525-4530, 1995
14. Ryan A, Al-Jehani RM, Mulligan KT, Jacobs U: No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol Oncol 68:14-17, 1998
15. Rodabaugh KJ, Biggs RB, Quresh JA, Barrett AJ, Welch WR, Bell DA, Berkowitz RS, Mok S: Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11:1249-1254, 1995
16. Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK: Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on chromosome 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55:2150-2157, 1995
17. INK4 in human ovarian cancers. Br J Cancer 76:146-149, 1997
18. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K, Murata Y: Alteration of p16 and p16 genes in common epithelial ovarian tumors. Int J Cancer (Pred Oncol) 74:148-155, 1997
19. Wolf JK, Bazzet L, Mills GB, Bast R, Roth JA, Gershenson DM: Growth inhibition of human ovarian cancer cells by transfection with adenovirus-mediated p53 is independent of endogenous p53 status. Proceedings of the 87th Annual American Association for Cancer Research, 1996.
20. Yaginuma Y, Westphal H: Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 54:1169-1174, 1992
21. Hurteau J, Rodriguez GC, Whitaker BS, Shah S, Mills G, Bast RC, et al.: Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74:93-99, 1994
22. Cancer Facts and Figures 1997. American Cancer Society, 1997
23. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991
24. INK4, the product of the putative tumor suppressor gene MTS1. Oncogene 9:3475-3482, 1994
25. Johnson DG: Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene 11:1685-1692, 1995
26. Hengstschlager M, Hengstschlager-Ottnad E, Pusch O, Wawra E: The role of p16 in E2F-dependent thymidine kinase regulation. Oncogene 12:1635-1643, 1996
27. Oswald F, Lovec H, Moroy T, Lipp M: E2F-dependent regulation of human MYC:trans-activation by cyclins D1 and A overrides tumor suppressor protein functions. Oncogene 9:2029-2036
28. Hamada K, Zhang W-W, Alemany R, Wolf J, Roth JA, Follen-Mitchell M: Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol Oncol 60:373-379, 1996
29. Zhang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA: High-efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:1-10, 1994
30. Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional regulation of the D-type cyclin-dependent kinase inhibitor p!6 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54:6078-6082, 1994
31. Fang X, Jin X, Xu H-J, Lui L, Hogg D, Yu Y, Xu F, Bast RC, Jr, Mills GB: Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16:1-8, 1998